Quarry LP Buys 2,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Quarry LP raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 33.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,000 shares of the company’s stock after purchasing an additional 2,500 shares during the period. Quarry LP’s holdings in BridgeBio Pharma were worth $255,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Profund Advisors LLC raised its position in BridgeBio Pharma by 1.1% during the 2nd quarter. Profund Advisors LLC now owns 51,029 shares of the company’s stock worth $1,293,000 after purchasing an additional 555 shares during the last quarter. Bfsg LLC raised its position in BridgeBio Pharma by 175.6% during the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after purchasing an additional 790 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in BridgeBio Pharma by 17.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock worth $135,000 after purchasing an additional 801 shares during the last quarter. Amalgamated Bank raised its position in BridgeBio Pharma by 24.7% during the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock worth $123,000 after purchasing an additional 962 shares during the last quarter. Finally, Diversified Trust Co raised its position in shares of BridgeBio Pharma by 3.0% in the 3rd quarter. Diversified Trust Co now owns 36,772 shares of the company’s stock worth $936,000 after acquiring an additional 1,059 shares in the last quarter. 99.85% of the stock is owned by institutional investors.

BridgeBio Pharma Stock Down 1.6 %

Shares of NASDAQ BBIO opened at $26.66 on Friday. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $44.32. The stock’s 50 day moving average price is $25.17 and its 200-day moving average price is $26.12. The company has a market capitalization of $5.04 billion, a PE ratio of -11.06 and a beta of 1.08.

Insider Transactions at BridgeBio Pharma

In other BridgeBio Pharma news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the sale, the insider now owns 25,260,971 shares of the company’s stock, valued at $650,470,003.25. The trade was a 18.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Neil Kumar sold 27,389 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49. Following the completion of the transaction, the chief executive officer now directly owns 4,897,443 shares in the company, valued at approximately $109,751,697.63. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,831,545 shares of company stock worth $150,056,923 in the last 90 days. Insiders own 24.66% of the company’s stock.

Analyst Ratings Changes

BBIO has been the subject of several research analyst reports. HC Wainwright lifted their price objective on BridgeBio Pharma from $43.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Scotiabank lifted their price objective on BridgeBio Pharma from $45.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, November 25th. Leerink Partners lowered their price objective on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Oppenheimer initiated coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a “market perform” rating for the company. Finally, Piper Sandler initiated coverage on BridgeBio Pharma in a research note on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 target price for the company. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.43.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.